Cord Blood News Volume 12.08 | Mar 5 2020

TOP STORY

Inferior Outcome of Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in First Complete Remission as Compared to De Novo Acute Myeloid Leukemia

To define the outcome of secondary acute myeloid leukemia (sAML) in the context of allogeneic stem cell transplantation, a retrospective, registry-based comparison was performed, including 11,439 patients with de novo and 1325 with sAML. [Blood Cancer J] Full Article

(Ranked by impact factor of the journal)

Different Culture Method Changing CD105 Expression in Amniotic Fluid MSCs without Affecting Differentiation Ability or Immune Function

Scientists demonstrated that amniotic fluid MSCs exhibited some advantages over umbilical cord MSCs, and different culture media caused cell proliferation, cell surface marker and cell morphology change, but were not associated with varying differentiation capability and immune effects. [J Cell Mol Med] Full Article

Therapeutic Effects of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Combined with Cartilage Acellular Matrix Mediated via Bone Morphogenic Protein 6 in a Rabbit Model of Articular Cruciate Ligament Transection

Treatment with cartilage acellular matrix significantly increased the expression of chondrogenic markers and BMP6 in umbilical cord blood-derived MSCs (UCB-MSCs). Treatment with recombinant human BMP6 also dramatically increased the levels of chondrogenic markers in UCB-MSCs. [Stem Cell Rev] Abstract

Decreased Immunomodulatory and Secretory Capability of Aging Human Umbilical Cord Mesenchymal Stem Cells In Vitro

Researchers compared the biological properties of human umbilical cord-MSCs (hUC-MSCs) at different passages, especially for immunomodulatory ability and secretions. They showed that hUC-MSCs at early passage and late passage (P8) exhibited similar morphology and surface marker expression, but hUC-MSCs at P8 displayed reduced proliferation and differentiation potential, immunoregulatory and secretory ability. [Biochem Biophys Res Commun] Abstract

Elevation of Stromal Cell-Derived Factor 1 and C-X-C Chemokine Receptor Type 4 in White Matter Damage Treatment with Recombinant Human Erythropoietin and Human Umbilical Cord Mesenchymal Stem Cells in a Rat Model of Preterm Birth

The recombinant human erythropoietin and human umbilical cord MSC intervention reduced injury area, increased body weight at postnatal day 7 (P7), and improved neurobehavioral scores at P28. Furthermore, their combined use proved even more beneficial. [Int J Dev Neurosci] Abstract

Human Umbilical Cord Mesenchymal Stem Cell-Derived and Dermal Fibroblast-Derived Extracellular Vesicles Protect Dermal Fibroblasts from Ultraviolet Radiation-Induced Photoaging In Vitro

Pre-treatment with MSC-derived extracellular vesicles or extracellular vesicles derived from dermal fibroblasts significantly inhibited the production of ROS induced by ultraviolet B (UVB) radiation, increased dermal fibroblast proliferation, protected cells against UVB-induced cell death and cell cycle arrest, and remarkably decreased the percentage of aged cells. [Photochem Photobiol Sci] Abstract

Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News.

Umbilical Cord Blood and Serum for the Treatment of Ocular Diseases: A Comprehensive Review

Researchers explore the clinical results that have been obtained using umbilical cord blood-derived products in the field of ophthalmology, as well as the current limitations of those products in this field. [Ophthalmol Ther] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

CytoDyn Treats First Patient with Leronlimab in Phase II Trial for GvHD under Modified Trial Protocol

CytoDyn Inc. announced the treatment of the first patient in its Phase II clinical trial for graft-versus-host disease (GvHD) under the modified trial protocol. [CytoDyn Inc.] Press Release

Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients

Actinium Pharmaceuticals, Inc. announced that it is expanding its CD33 program studying Actimab-A into a combination trial with the chemotherapy regimen 7+3 in patients with newly diagnosed acute myeloid leukemia who have intermediate or high-risk cytogenetic or molecular markers. [Actinium Pharmaceuticals, Inc.] Press Release

Scientists Grapple with US Restrictions on Fetal Tissue Research

The Trump administration’s changes to policy involving material donated from abortions have led scientists to adjust their research projects or seek alternative sources of funding. [The Scientist] Editorial

China Bans Cash Rewards for Publishing Papers

Chinese institutions have been told to stop paying researchers bonuses for publishing in journals, as part of a new national policy to cut perverse incentives that encourage scientists to publish lots of papers rather than focus on high-impact work. [Nature News] Editorial

NEW Tissue Engineering and Regenerative Medicine Asia-Pacific Conference 2020
September 21-24, 2020
Kuala Lumpur, Malaysia

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Researcher – Leukemia (Universitätsklinikum Carl Gustav Carus Dresden)

Postdoctoral Scientist – Stem Cell Biology (Cancer Research UK Manchester Institute)

PhD Student Position – Oral Biology and Medicine (Karolinska Institutet)

Research Technician – Graft versus Host Disease (Fred Hutchinson Cancer Research Center)

Laboratory Director – Cord Blood Processing (PerkinElmer)

Research Associate – Cell Culture (Rogosin Institute)

Tenure-Track/Tenured Faculty Positions – Biomedical Science (Southern University of Science and Technology)

Postdoctoral Fellow Positions – Epigenetics, 3D Bioprinting, Hematopoietic Stem Cell Biology, Bioengineering, and Blood Cancers (Childrens Hospital & Ohio State University)

Assistant or Associate Professor – Hematopoietic Cell Transplant Program (Fred Hutchinson Cancer Research Center)

Senior Research Scientist – Stem Cell Biology and Disease Modeling (Tata Institute for Genetics and Society)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here.